Proceeds to support clinical development of lead first-in-class program ONA-255 in breast cancer, toward clinical proof of concept, and advance ONA-389 in colorectal cancer
Read moreOna Therapeutics is a pioneer in the development of first-in-class antibody-drug conjugates (ADCs) that leverage the molecular basis of advanced cancer. Through collaboration with academic and clinica...
Read moreNature, the world's leading scientific journal, has spotlighted three Barcelona-based biotech startups, Ona Therapeutics, Nuage Therapeutics, and SpliceBio, in a recent article highlighting Spain's bu...
Read moreCovid-19 pandemic has boosted cutting-edge research and innovation, reaching a record investment for companies in the BioRegion
Read moreEl capital riesgo con participación internacional se incrementa un 67,1% y se erige como motor principal del crecimiento, según el Informe de la BioRegión 2020 - Retos en adelante, presentado por B...
Read moreOna Therapeutics, Aortyx, Glycardial, ABLE Human Motion y Pebble Analytics competirán en la final, el 28 de septiembre, para demostrar quién tiene el mejor 'pitch' de la BioRegión
Read moreOna Therapeutics, which is focused on the discovery and development of therapeutic biologics to treat metastatic cancer, announces today the closing of a €30 million Series A financing, with partici...
Read moreOna Therapeutics, spin-off del IRB Barcelona e ICREA, ha sido fundada por los investigadores Salvador Aznar-Benitah y Valerie Vanhooren tras la inversión liderada por Sabadell Asabys. La empresa, co...
Read more